Dr Charlotte Coles
Personal home page:
PubMed journal articles - click here
Dr Charlotte Coles is pleased to consider applications from prospective PhD students.
I lead a national portfolio of breast cancer RT studies and translational research which aims to provide breast cancer patients with the best chance of cure with least side effects:
IMPORT LOW (n=2018): intensity modulated radiotherapy (IMRT) and partial breast radiotherapy (PBRT) in patients at low risk of recurrence – in follow up
IMPORT HIGH (n=2621): dose-escalated IMRT for patients at higher risk of recurrence - in follow up
PRIMETIME (n=2200): Post-operative avoidance of RT in minimal risk women: patient selection using biomarkers – in set up
NEO-RT (n=50): pre-operative breast IMRT in patients receiving neo-adjuvant hormonal treatment – in set up
Potential benefit for
• Safe reduction of whole breast plus boost RT for high risk patients from 4.5 weeks to 3 weeks
• Minimising side effects whilst maintaining local control with PBRT for low risk patients
• Safe avoidance of RT for patients at very low risk of recurrence
• Possible avoidance of mastectomy following neo-adjuvant RT and endocrine therapy
• Development of molecular profiles to predict recurrence risk and normal tissue toxicity following RT
• Implementation of high quality IMRT and PBRT as standard of care
• Use of a cost-effective predictive marker for safe RT avoidance
• Reduction in number of fractions and RT avoidance saving the NHS >£12million/year
I am also editor of Clinical Oncology journal: www.clinicaloncologyonline.net/
Symplectic Elements feed provided by Research Information, University of Cambridge
1. Coles CE, Griffin C, Kirby A, Titley A, Agrawal R, Alhasso A, Bhattacharya I, Brunt M, Ciurlionis L, Chan C, Donovan E, Emson M, Harnett A, Haviland J, Hopwood, Jefford M, Kaggwa R, Sawyer E, Syndikus I, Tsang Y, Wheatley D, Wilcox M, Yarnold J, Bliss J, on behalf of the IMPORT Trialists’ Group. Partial breast radiotherapy after breast conservation surgery for early breast cancer: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III randomised controlled trial. Accepted by The Lancet, 13th April, 2017.
2. Coles CE, Fourquet A, Poortmans P. Preoperative radiation therapy: The 'new' targeted breast cancer treatment? Eur J Cancer. 2017 Apr 22;78:116-117.
3. Coles CE. Another piece in the jigsaw of accelerated partial breast irradiation. Lancet Oncol. 2017 Jan 13. pii: S1470-2045(17)30001-3.
4. Poortmans PMP, Coles CE, Bernier J. Treatment of regional lymph nodes in breast cancer: Evidence in favor of radiation therapy. JAMA Oncology 2016. 2; 8: 989-90.
5. Coles CE, Yarnold JR. Accelerated partial breast irradiation: the new standard? Lancet 2016. 387; 10015: 201-2.
6. Mukesh MB, Barnett GC, Wilkinson JS, Moody AM, Wilson CB, Dorling L, Chan Wah Hak C, Qian W, Twyman N, Burnet NG, Wishart GC and Coles CE. A randomised controlled trial of Intensity Modulated Radiotherapy (IMRT) for early breast cancer: 5-year results confirm superior overall cosmesis. Journal of Clinical Oncology 2013. 31; 36: 4488-95.